A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Br J Haematol
; 204(5): 1825-1829, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38286472
ABSTRACT
This phase II study evaluated time-limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenström macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable patients with no patient achieving a complete response (CR). The median duration of treatment was 15.6 months, and after a median follow-up time of 25.7 months, the median progression-free survival (PFS) was 22.9 months. While the primary end-point was not met (CR rate at any time) and 28.5% discontinued treatment due to toxicity, ibrutinib plus ixazomib led to a clinically meaningful ORR and PFS. Combined Bruton's tyrosine kinase (BTK) and proteasome inhibition merits further evaluation in WM.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piperidinas
/
Compuestos de Boro
/
Adenina
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Macroglobulinemia de Waldenström
/
Glicina
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2024
Tipo del documento:
Article